Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 3 (1)

Trial Status

Unknown1
Withdrawn1

Clinical Trials (2)

Showing 2 of 2 trials
NCT00406120Withdrawn

Validation of a Molecular Prognostic Test for Eye Melanoma

NCT00000124Phase 3UnknownPrimary

Collaborative Ocular Melanoma Study (COMS)

Showing all 2 trials

Research Network

Activity Timeline